Eisai And Biogen Say Canada's Drug Agency Issued Final Positive Recommendation Supporting Public Reimbursement Of Leqembi For Early Alzheimer's Disease
Share
Why It Matters
Canada's health agency said yes to helping people pay for a new Alzheimer's medicine that Eisai and Biogen made together. This means more patients in Canada can now use this drug, which is good news for the company's business.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.